hotspot -WSS

hotspot

author：entertainment 2025-09-27 23:01:16 - browse：4

glum Benjamin — health insurance coverage from STAT — Adobe

Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences.

Scion was started by former Apple Tree Partners colleagues Sam Hall and Aaron Kantoff, along with Tadd Wessel, managing partner of the health care private equity firm Petrichor. They raised $310 million for its first fund, blowing past their original $250 million target.

They’re planning on taking a different tack with biotech venture capital. For starters, Scion plans to work on a significantly longer timeframe. Most firms in existence today write checks, help investments grow, and find a way to recoup their money in a 10-year timeframe. Scion is doubling that, setting a 20-year plan for its first fund.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： The problem with charging patients to message their doctors

entertainment

focus

WSS

Illumina names Agilent executive as new CEO

In his State of the Union, Biden takes clear aim at 'Big Pharma'

RSV shot was 90% effective at preventing hospitalizations in kids

How to fix cancer clinical trials' diversity problem

How to fix cancer clinical trials' diversity problem

How to fix cancer clinical trials' diversity problem

explore

hotspot

focus

United colonoscopy coverage change 'may cost lives,' doctors say

First medicine developed to treat MASH expected to be approved soon

Hepatitis C has a cure — but many Americans still lack access to it

Stem cell treatment guidelines are released by FDA

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Covid hospitalizations on the rise, Humana says

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

First medicine developed to treat MASH expected to be approved soon

Medicare details structure of new drug price negotiation program

What drug price negotiations mean for Medicare Part D

focus

A new House health package & hospitals’ new site

How to fix cancer clinical trials' diversity problem

Stem cell treatment guidelines are released by FDA

How generative AI is inspiring dreams of a health data revolution

AstraZeneca chief proposes a novel edit to the drug pricing bill

The problem with charging patients to message their doctors

entertainment

entertainment

focus

hotspot